A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03, a CD19-Targeting Antibody Drug Conjugate (ADC), in Patients with Advanced B cell Non-Hodgkin Lymphomas (NHL).
Contact Information for Access
Status
ATTIVO
Objective of the study
The study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics, and pharmacodynamics of IKS03, an anti-CD19 drug-antibody conjugate, in patients with advanced B-cell non-Hodgkin lymphoma (NHL).
ClinicalTrials.gov ID NCT05365659
Sponsor: Iksuda Therapeutics Ltd.
Medication
IKS03 (anti-CD19 antibody).
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with CD19-positive or unknown CD19 status non-Hodgkin lymphoma who have received at least two prior lines of therapy.
View the full study Back to search page